Intra-Cellular Therapies is a leading biopharmaceutical company founded by Nobel Prize winner Paul Greengard to address neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. It is launching its 1st product, Caplyta, an important new product for the treatment of schizophrenia and bipolar disorders.

‍

‍